quarta-feira, 7 de outubro de 2026

Pesquisar Explore

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· February 23, 2026

Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says

View original at finance.yahoo.com

Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

Institutional investors in Hong Kong and UAE are leveraging natural resources to buy and hold Bitcoin
80% confidence
Institutional investors are investing very heavily in adopting blockchain technology for infrastructure
80% confidence
Bitcoin's recent decline is a setup seen multiple times before
80% confidence
Bitcoin unlikely to reach $15,000 levels again due to reduced volatility and favorable U.S. administration
80% confidence
Middle East investors use fossil fuel sales for Bitcoin investment, China uses trade surpluses
80% confidence
Institutional investors have been investing consistently over past five to seven years, not just buying the dip
80% confidence
10-year returns: S&P made 2.5x, gold made 3x, Bitcoin made 11,000-15,000x
80% confidence
Net buying exceeds net selling on Coinbase platform
80% confidence
Institutional investors' thesis of Bitcoin as store of value has not changed despite price volatility
80% confidence

Data points we hold from this source

Elf Labs · trademarks copyrights

500 count

O que sabemos · a inteligência por trás desta página

Ao vivo do substrato

O que estamos a ver

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

A nossa leitura dos dados ›

Sinais que acompanhamos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Padrões que observamos ›

Onde as fontes divergem

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Sinalizamos conflitos abertamente ›

Verificado recentemente

✓ Verificado com a fonte original

4,986

factos rastreados à sua fonte — e sinalizamos os que não se confirmam.

101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados

Consulte estes dados → isubstrate.com

Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says — Source | Via News | pt.VIA.NEWS